AU2023219232A1 - Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine - Google Patents
Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine Download PDFInfo
- Publication number
- AU2023219232A1 AU2023219232A1 AU2023219232A AU2023219232A AU2023219232A1 AU 2023219232 A1 AU2023219232 A1 AU 2023219232A1 AU 2023219232 A AU2023219232 A AU 2023219232A AU 2023219232 A AU2023219232 A AU 2023219232A AU 2023219232 A1 AU2023219232 A1 AU 2023219232A1
- Authority
- AU
- Australia
- Prior art keywords
- combination
- pharmaceutical combination
- arginine
- sildenafil
- pde5 inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pulmonology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| TW111104639A TWI859506B (zh) | 2022-02-09 | 2022-02-09 | 化合物組合用於製作血管疾病治療藥的用途 |
| TW111104639 | 2022-02-09 | ||
| PCT/GB2023/050296 WO2023152500A1 (en) | 2022-02-09 | 2023-02-09 | Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2023219232A1 true AU2023219232A1 (en) | 2024-07-25 |
Family
ID=85283927
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023219232A Pending AU2023219232A1 (en) | 2022-02-09 | 2023-02-09 | Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20250134892A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4475833A1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP2025504219A (cg-RX-API-DMAC10.html) |
| KR (1) | KR20240146018A (cg-RX-API-DMAC10.html) |
| CN (1) | CN116808224A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2023219232A1 (cg-RX-API-DMAC10.html) |
| TW (1) | TWI859506B (cg-RX-API-DMAC10.html) |
| WO (1) | WO2023152500A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI879058B (zh) * | 2023-08-31 | 2025-04-01 | 未來新藥股份有限公司 | Pde5抑制劑組合於促進神經突生長之新穎用途 |
| CN122055146A (zh) * | 2023-08-31 | 2026-05-15 | 未来新药股份有限公司 | Pde5抑制剂组合于促进神经突生长的新颖用途 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4699299A (en) | 1998-06-26 | 2000-01-17 | Nutracorp Scientific, Inc. | Promoting nitric oxide and cyclic gmp activity |
| IL132460A0 (en) * | 1999-10-19 | 2001-03-19 | Laniado Shlomo | Sildenafil preparation |
-
2022
- 2022-02-09 TW TW111104639A patent/TWI859506B/zh active
-
2023
- 2023-02-09 WO PCT/GB2023/050296 patent/WO2023152500A1/en not_active Ceased
- 2023-02-09 CN CN202310100652.1A patent/CN116808224A/zh active Pending
- 2023-02-09 US US18/836,532 patent/US20250134892A1/en active Pending
- 2023-02-09 JP JP2024547249A patent/JP2025504219A/ja active Pending
- 2023-02-09 KR KR1020247028842A patent/KR20240146018A/ko active Pending
- 2023-02-09 AU AU2023219232A patent/AU2023219232A1/en active Pending
- 2023-02-09 EP EP23706081.9A patent/EP4475833A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN116808224A (zh) | 2023-09-29 |
| US20250134892A1 (en) | 2025-05-01 |
| TW202332450A (zh) | 2023-08-16 |
| EP4475833A1 (en) | 2024-12-18 |
| KR20240146018A (ko) | 2024-10-07 |
| WO2023152500A1 (en) | 2023-08-17 |
| JP2025504219A (ja) | 2025-02-06 |
| TWI859506B (zh) | 2024-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guo et al. | Anti-fibrotic effects of puerarin on CCl4-induced hepatic fibrosis in rats possibly through the regulation of PPAR-γ expression and inhibition of PI3K/Akt pathway | |
| WO2002003996A1 (en) | Use of dammarane-type tritepenoid saporins | |
| JP4411414B2 (ja) | 糖尿病性神経障害の治療に対する組成物及びその方法 | |
| US20250134892A1 (en) | Combination of compounds for treating vascular diseases comprising pde5 inhibitor, arginine and n-acetylcysteine | |
| US9289401B2 (en) | Nutritional supplements | |
| CN112654264A (zh) | 使用至少一种甘氨酸或其衍生物、至少一种n-乙酰半胱氨酸或其衍生物和至少一种烟酰胺核糖核苷或nad+前体的组合物和方法 | |
| RU2014101261A (ru) | Системы, способы и составы для лечения рака | |
| Fuentes et al. | Protection against indomethacin-induced loss of intestinal epithelial barrier function by a quercetin oxidation metabolite present in onion peel: In vitro and in vivo studies | |
| KR100516827B1 (ko) | 일산화질소생산억제제 | |
| KR101516677B1 (ko) | 지방성 간 질환의 치료용 의약 조성물 | |
| WO2021230146A1 (ja) | Nr及び/又はnmnとセサミン類とを含有する組成物 | |
| KR19980070878A (ko) | 새로운 진통제 조성물 | |
| WO2025026900A1 (en) | Compounds for the treatment or prevention of gout | |
| US20210128596A1 (en) | Compositions and methods for treating septic cardiomyopathy | |
| JP2024016228A (ja) | アセトアミノフェン(apap)によって引き起こされる毒性を予防、低減または根絶するための方法および組成物 | |
| JP2022550312A (ja) | Fxrアゴニストの使用を含む処置 | |
| US20250009692A1 (en) | Micronutrient composition to prevent and reverse protein glycation during oxidative stress in human | |
| TWI451866B (zh) | 治療及預防患者因心肌缺血所引起的不適的醫藥組合物 | |
| KR20250098567A (ko) | 한속단 추출물을 유효성분으로 포함하는 신경병증성 통증 예방 또는 치료용 약학 조성물 | |
| JP4896531B2 (ja) | 血中CoQ10量を増加させる医薬組成物 | |
| CN101756984B (zh) | 吡咯并喹啉醌在治疗和预防动脉粥样硬化中的应用 | |
| AU2023225518A1 (en) | Chromanol compounds for treatment or prophylaxis of ageing-associated disorders | |
| HK40089668A (en) | Composition containing sesamin or like and nr and/or nmn | |
| BR112021002855B1 (pt) | Usos de pelo menos uma glicina ou de um derivado da mesma, de pelo menos uma n-acetilcisteína ou de um derivado da mesma e de pelo menos um ribosídeo de nicotinamida ou de um precursor de nad+ , composições compreendendo os mesmos, e kit | |
| HK40050780A (en) | Compositions and methods using at least one glycine or derivative thereof, at least one n-acetylcysteine or derivative thereof, and at least one nicotinamide riboside or nad+ precursor |